Works matching IS 03407004 AND DT 2022 AND VI 71 AND IP 10


Results: 22
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    CMTM6 as a master regulator of PD-L1.

    Published in:
    Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2325, doi. 10.1007/s00262-022-03171-y
    By:
    • Yaseen, Mahmoud Mohammad;
    • Abuharfeil, Nizar Mohammad;
    • Darmani, Homa
    Publication type:
    Article
    12

    Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy.

    Published in:
    Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2421, doi. 10.1007/s00262-022-03170-z
    By:
    • Sato, Yosuke;
    • Casson, Cierra N.;
    • Matsuda, Atsushi;
    • Kim, James I.;
    • Shi, Judy Qiuju;
    • Iwasaki, Shinji;
    • Chen, Susan;
    • Modrell, Brett;
    • Chan, Chingkit;
    • Tavares, Daniel;
    • Austen, Douglas;
    • Ida, Koh;
    • Tayber, Olga;
    • Hein, Pyae;
    • Comeau, Robert;
    • Lin, Yafang;
    • Shaw, Michael H.
    Publication type:
    Article
    13

    Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors.

    Published in:
    Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2405, doi. 10.1007/s00262-022-03169-6
    By:
    • Shaikh, Fyza Y.;
    • Gills, Joell J.;
    • Mohammad, Fuad;
    • White, James R.;
    • Stevens, Courtney M.;
    • Ding, Hua;
    • Fu, Juan;
    • Tam, Ada;
    • Blosser, Richard L.;
    • Domingue, Jada C.;
    • Larman, Tatianna C.;
    • Chaft, Jamie E.;
    • Spicer, Jonathan D.;
    • Reuss, Joshua E.;
    • Naidoo, Jarushka;
    • Forde, Patrick M.;
    • Ganguly, Sudipto;
    • Housseau, Franck;
    • Pardoll, Drew M.;
    • Sears, Cynthia L.
    Publication type:
    Article
    14
    15
    16
    17
    18
    19

    Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers.

    Published in:
    Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2371, doi. 10.1007/s00262-022-03160-1
    By:
    • Zheng, Yulong;
    • Mislang, Anna Rachelle Austria;
    • Coward, Jermaine;
    • Cosman, Rasha;
    • Cooper, Adam;
    • Underhill, Craig;
    • Zhu, Jianqing;
    • Xiong, Jianping;
    • Jiang, Ou;
    • Wang, Hong;
    • Xie, Yanru;
    • Zhou, Yuefen;
    • Jin, Xiaoping;
    • Li, Baiyong;
    • Wang, Zhongmin Maxwell;
    • Kwek, Kon Yew;
    • Xia, Dennis;
    • Xia, Yu;
    • Xu, Nong
    Publication type:
    Article
    20

    Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial.

    Published in:
    Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2485, doi. 10.1007/s00262-022-03159-8
    By:
    • Loeb, David M.;
    • Lee, Ji Won;
    • Morgenstern, Daniel A.;
    • Samson, Yvan;
    • Uyttebroeck, Anne;
    • Lyu, Chuhl Joo;
    • Van Damme, An;
    • Nysom, Karsten;
    • Macy, Margaret E.;
    • Zorzi, Alexandra P.;
    • Xiong, Julia;
    • Pollert, Petra;
    • Joerg, Ingrid;
    • Vugmeyster, Yulia;
    • Ruisi, Mary;
    • Kang, Hyoung Jin
    Publication type:
    Article
    21

    VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients.

    Published in:
    Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2355, doi. 10.1007/s00262-022-03156-x
    By:
    • Khan, ANM Nazmul H.;
    • Emmons, Tiffany R.;
    • Magner, William J.;
    • Alqassim, Emad;
    • Singel, Kelly L.;
    • Ricciuti, Jason;
    • Eng, Kevin H.;
    • Odunsi, Kunle;
    • Tomasi, Thomas B.;
    • Lee, Kelvin;
    • Abrams, Scott I.;
    • Mesa, Circe;
    • Segal, Brahm H.
    Publication type:
    Article
    22